Convatec Group Plc (CNVVY), a medical products and technologies company, on Tuesday said that it is on track to deliver full-year double-digit adjusted earnings per share or EPS growth guidance.
The company has also raised organic sales growth guidance, citing a trading growth across all categories.
The Group now expects annual organic sales growth of 7.25 percent to 8 percent against previous expectation of 6 percent to 7 percent.
Annual capital expenditure guidance still anticipated to be in the range of $120 million to140 million.
Karim Bitar, CEO of Convatec, said: "Convatec has delivered faster broad-based sales growth in the second half and operating margin is tracking materially ahead of H1, driven by strong execution of our FISBE strategy and lower inflation. We are on-track to deliver a mid-20s operating margin in 2026 or 2027."
For the full-year 2025, the Group expects to further expand operating margin and deliver double-digit adjusted EPS.
This would be driven by 5 percent to 7 percent organic growth in non-InnovaMatrix sales, 96 percent of the Group, based on the broadening product portfolio, new product launches, ongoing productivity initiatives, and others.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.